Andriy Yagensky

Scopus Publications

Sex differences in baseline characteristics, stroke care, and outcomes across socioeconomic settings: a multicentre study from Switzerland, Poland, and Ukraine
Charlotte Berger, Helly Hammer, Marino Costa, Pawel Lowiec, Andriy Yagensky, et al.
Journal of Neurology, 2026
Baseline characteristics, reperfusion treatment secondary prevention and outcome after acute ischemic stroke in three different socioeconomic environments in Europe
Charlotte Berger, Helly Hammer, Marino Costa, Pawel Lowiec, Andriy Yagensky, et al.
European Stroke Journal, 2024
Introduction: The differences in vascular risk factors’ and stroke burden across Europe are notable, however there is limited understanding of the influence of socioeconomic environment on the quality of secondary prevention and outcome after acute ischemic stroke. Patients and methods: In this observational multicenter cohort study, we analyzed baseline characteristics, reperfusion treatment, outcome and secondary prevention in patients with acute ischemic stroke from three tertiary-care teaching hospitals with similar service population size in different socioeconomic environments: Bern/CH/n = 293 (high-income), Gdansk/PL/n = 140 (high-income), and Lutsk/UA/n = 188 (lower-middle-income). Results: We analyzed 621 patients (43.2% women, median age = 71.4 years), admitted between 07 and 12/2019. Significant differences were observed in median BMI (CH = 26/PL = 27.7/UA = 27.8), stroke severity [(median NIHSS CH = 4(0-40)/PL = 11(0-33)/UA = 7(1-30)], initial neuroimaging (CT:CH = 21.6%/PL = 50.7%/UA = 71.3%), conservative treatment (CH = 34.1%/PL = 38.6%/UA = 95.2%) (each p &lt; 0.001), in arterial hypertension (CH = 63.8%/PL = 72.6%/UA = 87.2%), atrial fibrillation (CH = 28.3%/PL = 41.4%/UA = 39.4%), hyperlipidemia (CH = 84.9%/PL = 76.4%/UA = 17%) (each p &lt; 0.001) and active smoking (CH = 32.2%/PL = 27.3%/UA = 10.2%) (p &lt; 0.007). Three-months favorable outcome (mRS = 0–2) was seen in CH = 63.1%/PL = 50%/UA = 59% (unadjusted-p = 0.01/adjusted-p CH-PL/CH-UA = 0.601/0.981), excellent outcome (mRS = 0–1) in CH = 48.5%/PL = 32.1%/UA = 27% (unadjusted-p &lt; 0.001/adjusted-p CH-PL/CH-UA = 0.201/0.08 and adjusted-OR CH-UA = 2.09). Three-months mortality was similar between groups (CH = 17.2%/PL = 15.7%/UA = 4.8%) (unadjusted-p = 0.71/adjusted-p CH-PL/CH-UA = 0.087/0.24). Three-months recurrent stroke/TIA occurred in CH = 3.1%/PL = 10.7%/UA = 3.1%, adjusted-p/OR CH-PL = 0.04/0.32). Three-months follow-up medication intake rates were the same for antihypertensives. Statin/OAC intake was lowest in UA = 67.1%/25.5% (CH = 87.3%/39.2%/unadjusted-p &lt; 0.001/adjusted-p CH-UA = 0.02/0.012/adjusted-OR CH-UA = 2.33/2.18). Oral intake of antidiabetics was lowest in CH = 10.8% (PL = 15.7%/UA = 16.1%/unadjusted-p = 0.245/adjusted-p CH-PL/CH-UA = 0.061/0.002/adjusted-OR CH-UA = 0.25). Smoking rates decreased in all groups during follow-up. Discussion and conclusion: Substantial differences in presentation, treatment and secondary prevention measures, are linked to a twofold difference in adjusted 3-months excellent outcome between Switzerland and Ukraine. This underscores the importance of socioeconomic factors that influence stroke outcomes, emphasizing the necessity for targeted interventions to address disparities in treatment and secondary prevention strategies.
I International scientific and practical conference “Doctors and nursing – medical front in Ukraine and the world”
Tetyana Pastryk, Olga Gershuni, Alla Lazko, Alla Yaremko, Halyna Martyniuk, et al.
Proceedings of the Shevchenko Scientific Society Medical Sciences, 2023
On May 11–12, 2023, the I International Scientific Practical Conference “Doctors and Nursing – Medical Front in Ukraine and the World” took place in Lutsk, Ukraine. The conference was dedicated to the 150th anniversary of the Shevchenko Scientific Society (SSS).The conference was organized by the Municipal Institution of Higher Education Volyn Medical Institute of Volyn Region Council, in collaboration with Danylo Halytsky Lviv National Medical University, I.Y. Horbachevsky Ternopil National Medical University, Vilnius University (Lithuania), Higher Private Educational Institution Lviv Medical University, the Shevchenko Scientific Society, and Health Tech Without Borders (Switzerland, USA). The conference was held with the support of the State Institution “Center for Nursing Development of the Ministry of Health of Ukraine”. Partners in conference organization also included Volyn Orthodox Theological Academy, Maastricht University (the Netherlands), Volyn Region Emergency Medical Center and Disaster Medicine Municipal Enterprise, German-Ukrainian Association of Nurses, NeanderklinikHarzwald (Germany), “Myloserdia” Association of Volyn Nurses PO and Lviv Association of Allergists, Immunologists, and Rehabilitologists Charitable Organization.During the course of the event, a total of over 100 speeches were delivered by medical scientists and practicing physicians, as well as researchers in diverse disciplines from Ukraine, the United States, Great Britain, Poland, Lithuania, Germany, the Netherlands, and Switzerland. Workshops were conducted on relevant issues in medical practice in times of war.A total of approximately 1100 individuals participated in the conference, comprising physicians from diverse disciplines and nurses, emergency medical professionals and disaster medicine specialists, scientific and pedagogical personnel, employees of the State Emergency Service, physical rehabilitation specialists, psychologists, representatives of the clergy and public organizations, and young scientists.A new interdisciplinary format of scientific dialogue has been started between representatives of medical and nursing specialities, the education sector, psychologists, and clergy. It helps find ways to address relevant issues in the medical sector in complex conditions of the present day.
Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial
Markus P Schlaich, Marc Bellet, Michael A Weber, Parisa Danaietash, George L Bakris, et al.
Lancet, 2022
Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
Gregory G. Schwartz, Michael Szarek, Vera A. Bittner, Rafael Diaz, Shaun G. Goodman, et al.
Journal of the American College of Cardiology, 2021
Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF
Sylvia Haas, A John Camm, Jean-Pierre Bassand, Pantep Angchaisuksiri, Frank Cools, et al.
American Heart Journal, 2019
Analysis of Outcomes in Ischemic vs Nonischemic Cardiomyopathy in Patients with Atrial Fibrillation: A Report from the GARFIELD-AF Registry
Ramon Corbalan, Jean-Pierre Bassand, Laura Illingworth, Giuseppe Ambrosio, A. John Camm, et al.
JAMA Cardiology, 2019
Alirocumab and cardiovascular outcomes after acute coronary syndrome
Gregory G. Schwartz, P. Gabriel Steg, Michael Szarek, Deepak L. Bhatt, Vera A. Bittner, et al.
New England Journal of Medicine, 2018
Rivaroxaban for thromboprophylaxis after hospitalization for medical illness
Alex C. Spyropoulos, Walter Ageno, Gregory W. Albers, C. Gregory Elliott, Jonathan L. Halperin, et al.
New England Journal of Medicine, 2018
Long-term outcomes after acute myocardial infarction in countries with different socioeconomic environments: An international prospective cohort study
Judith Kämpfer, Andriy Yagensky, Tomasz Zdrojewski, Stephan Windecker, Bernhard Meier, et al.
BMJ Open, 2017
Background Hospital-based data on the impact of socioeconomic environment on long-term survival after myocardial infarction (MI) are lacking. We compared outcome and quality of secondary prevention in patients after MI living in three different socioeconomic environments including patients from three tertiary-care teaching hospitals with similar service population size in Switzerland, Poland and Ukraine. Methods This is a prospective cohort study of patients with a first MI in three different tertiary-care teaching hospitals in Bern (Switzerland), Gdansk (Poland) and Lutsk (Ukraine) during the acute phase in the year 2010 and follow-up of these patients with a questionnaire and, if necessary, telephone interviews 3.5 years after the acute event. The study cohort comprises all consecutive patients hospitalised in every one of the three study centres during the year 2010 for a first MI in the age ≤75 years who survived ≥30 days. Results The proportion of patients with ST-segment elevation myocardial infarction (STEMI) was high in Gdansk (Poland) (80%) and in Lutsk (Ukraine) (74%), while the ratio of STEMIs to non-STEMIs was nearly 50:50 in Bern (Switzerland) (50.6% STEMIs). Percutaneous coronary intervention (PCI) was the first choice therapy both in Bern (Switzerland) (100%) and in Gdansk (Poland) (92%), while it was not performed at all in Lutsk (Ukraine). We found substantial differences in treatment and also in secondary prevention interventions including cardiac rehabilitation. All-cause mortality at 3.5 year follow-up was 4.6% in Bern (Switzerland), 8.5% in Gdansk (Poland) and 14.6% in Lutsk (Ukraine). Conclusion Substantial differences in treatment and secondary prevention measures according to low-income, middle-income and high-income socioeconomic situation are associated with a threefold difference in mortality 3.5 years after the acute event. Countries with low socioeconomic environment should increase efforts and be supported to improve care including secondary prevention in particular for MI patients. A greater number of PCIs per million inhabitants itself does not guarantee lower mortality scores.
Comparison of fatal or irreversible events with extended-duration betrixaban versus standard dose enoxaparin in acutely Ill medical patients: An APEX trial substudy
C. Michael Gibson, Serge Korjian, Gerald Chi, Yazan Daaboul, Purva Jain, et al.
Journal of the American Heart Association, 2017
Effects of the lercanidipine - Enalapril combination vs. The corresponding monotherapies on home blood pressure in hypertension: Evidence from a large database
Giuseppe Mancia, Stefano Omboni, Irina Chazova, Antonio Coca, Xavier Girerd, et al.
Journal of Hypertension, 2016
Angina and future cardiovascular events in stable patients with coronary artery disease: Insights from the Reduction of Atherothrombosis for Continued Health (REACH) registry
Alon Eisen, Deepak L. Bhatt, P. Gabriel Steg, Kim A. Eagle, Shinya Goto, et al.
Journal of the American Heart Association, 2016
Erratum: Effect of darapladib on major coronary events after an acute coronary syndrome: The SOLID-TIMI 52 randomized clinical trial (JAMA (2014) 312:10(1006-1015))
Michelle L. O’Donoghue, Eugene Braunwald, Harvey D. White, Dylan P. Steen, Mary Ann Lukas, et al.
JAMA Journal of the American Medical Association, 2014
Effect of darapladib on major coronary events after an acute coronary syndrome: The SOLID-TIMI 52 randomized clinical trial
Michelle L. O’Donoghue, Eugene Braunwald, Harvey D. White, Dylan P. Steen, Mary Ann Lukas, et al.
JAMA Journal of the American Medical Association, 2014
Prasugrel versus clopidogrel for acute coronary syndromes without revascularization
Matthew T. Roe, Paul W. Armstrong, Keith A.A. Fox, Harvey D. White, Dorairaj Prabhakaran, et al.
New England Journal of Medicine, 2012
Assessment of the quality of secondary ischemic stroke prevention in selected urban areas of Poland and Ukraine: The ASCEP study results
K. Chwojnicki, A. Yagensky, L. Wierucki, I. Sichkaruk, N. Sydor, et al.
European Neurology, 2011
Preliminary evidence for the cross-cultural utility of the type D personality construct in the Ukraine
Susanne S. Pedersen, Andriy Yagensky, Otto R. F. Smith, Oksana Yagenska, Volodymyr Shpak, et al.
International Journal of Behavioral Medicine, 2009
Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: A randomized controlled trial
M. Jadzinsky, A. Pfützner, E. Paz‐Pacheco, Z. Xu, E. Allen, et al.
Diabetes Obesity and Metabolism, 2009

Andriy Yagensky

RESEARCH, TEACHING, or OTHER INTERESTS

Scopus Publications